Evolocumab

High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.

Amgen announced that the FDA has approved evolocumab as an adjunct to diet and other LDL-lowering therapies for the treatment of heterozygous familial hypercholesterolemia in pediatric patients aged 10 years and older.